Gastrointestinal Diseases  >>  Inlyta (axitinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inlyta (axitinib) / Pfizer
NCT00219557 / 2005-000053-30: AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

Completed
2
111
Canada, US, Europe
Gemcitabine, AG-013736
Pfizer
Pancreatic Neoplasms
03/08
03/08
NCT00615056 / 2007-006283-30: A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

Checkmark Data-ASCO
Feb 2011 - Feb 2011: Data-ASCO
Checkmark Data - CRC
Feb 2011 - Feb 2011: Data - CRC
Completed
2
171
Japan, US, Canada, Europe, RoW
Bevacizumab (avastin), FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])
Pfizer
Colorectal Neoplasms
03/11
04/12
NCT01210495 / 2010-021590-37: Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
2
224
Japan, US, Europe, RoW
Axitinib (AG-013736), Best Supportive Care, Placebo
Pfizer
Hepatocellular Carcinoma
03/14
12/16
NCT00460603: Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer

Checkmark
Apr 2013 - Apr 2013: 
Checkmark Data-ASCO
Feb 2011 - Feb 2011: Data-ASCO
Completed
1/2
187
US
bevacizumab, AG-013726, AG-013736 (axitinib)
Pfizer
Colorectal Neoplasms
04/12
11/12

Download Options